Vistex Inc articles

The COVID pandemic has created a shift in our landscape—challenging brands with building and maintaining their brand loyalty—as our idea of business as usual continues to evolve. As in-person events give way to virtual environments, how can you maintain brand loyalty with your customers? In the past, events have been leveraged to create unique experiences, inviting customers to participate in your brand and ideally generate lasting impressions. Our current state of business provid

In the next few months, most retail and foodservice CPG (Consumer Packaged Goods) manufacturers like you, will be starting their annual process for 2021 S&OP (Sales & Operations Planning). Even during “ordinary times” this is an arduous process:

• Rolling out volume targets to plan customers
• Defining trade spend budget targets to drive growth through available merchandising conditions
• Launching new items
• Getting

When 20th century sci-fi looked to the distant future, did you ever imagine the world would look like it does today? Well, to be fair, we didn’t factor in a global pandemic. And now, the entire wholesale distribution sector has been impacted. While we may not be driving flying cars or holidaying on Mars (yet), our technology is revolutionizing our ability to pivot dynamically. The most successful wholesale distributors right now are the ones who have quickly become scalable in handling

In February of 2019, CEOs and senior executives from seven major pharmaceutical companies met with the Senate Finance Committee about drug pricing. During that meeting, AstraZeneca CEO Pascal Soriot discussed how value-based agreements have the potential to transform how medicines are priced and reimbursed in the U.S., and in doing so, triggered a host of discussions across the industry on the topic. And with healthcare

The risk? According to Medicinenet.com, only 5 in 5,000 drugs that enter preclinical testing advance to human trials. And only 1 of these 5 drugs ultimately gets approved for sale, which means the chance for a new drug to make it to market is 1 in 5,000. That’s a lot of R&D investment.